Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Interest & Investment Income: 2016-2024

Historic Interest & Investment Income for Rhythm Pharmaceuticals (RYTM) over the last 8 years, with Dec 2024 value amounting to $14.7 million.

  • Rhythm Pharmaceuticals' Interest & Investment Income rose 6.76% to $4.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $14.7 million, marking a year-over-year decrease of 1.94%. This contributed to the annual value of $14.7 million for FY2024, which is 5.49% up from last year.
  • Rhythm Pharmaceuticals' Interest & Investment Income amounted to $14.7 million in FY2024, which was up 5.49% from $13.9 million recorded in FY2023.
  • In the past 5 years, Rhythm Pharmaceuticals' Interest & Investment Income ranged from a high of $14.7 million in FY2024 and a low of $447,000 during FY2021.
  • For the 3-year period, Rhythm Pharmaceuticals' Interest & Investment Income averaged around $10.9 million, with its median value being $13.9 million (2023).
  • Data for Rhythm Pharmaceuticals' Interest & Investment Income shows a peak YoY spiked of 801.34% (in 2022) over the last 5 years.
  • Yearly analysis of 4 years shows Rhythm Pharmaceuticals' Interest & Investment Income stood at $447,000 in 2021, then soared by 801.34% to $4.0 million in 2022, then soared by 246.12% to $13.9 million in 2023, then grew by 5.49% to $14.7 million in 2024.